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The persistence of serum IgG antibodies
elicited in human infants is much shorter
than when such responses are elicited
later in life. The reasons for this rapid
waning of antigen-specific antibodies elic-
ited in infancy are yet unknown. We have
recently shown that adoptively trans-
ferred tetanus toxoid (TT)–specific plas-
mablasts (PBs) efficiently reach the bone
marrow (BM) of infant mice. However,
TT-specific PBs fail to persist in the early-
life BM, suggesting that they fail to re-
ceive the molecular signals that support
their survival/differentiation. Using a
proliferation-inducing ligand (APRIL)– and
B-cell activating factor (BAFF) B-
lymphocyte stimulator (BLyS)–deficient
mice, we demonstrate here that APRIL is
a critical factor for the establishment of
the adult BM reservoir of anti-TT IgG-
secreting cells. Through in vitro analyses
of PB/plasma cell (PC) survival/differentia-
tion, we show that APRIL induces the
expression of Bcl-XL by a preferential
binding to heparan sulfate proteoglycans
at the surface of CD138 cells. Last, we
identify BM-resident macrophages as the
main cells that provide survival signals to
PBs and show that this function is slowly
acquired in early life, in parallel to a
progressive acquisition of APRIL expres-
sion. Altogether, this identifies APRIL as a
critical signal for PB survival that is poorly
expressed in the early-life BM compart-
ment. (Blood. 2008;111:2755-2764)
© 2008 by The American Society of Hematology
Introduction
The limitations of antibody responses that may be elicited early in
life contribute to high morbidity and mortality from infectious
diseases among young children. It has long been recognized that
infant IgG responses following natural infection or immunization
are weaker than those elicited at a later stage of immune matura-
tion.1-10 Moreover, the persistence of IgG generated before 1 year
of age is shorter than when such responses are elicited later.11-15
This early waning of IgG may result in a resurgence of vulnerabil-
ity to infection,15,16 unless vaccine boosters are given in the second
year of life. The reasons for this rapid waning of antigen-specific
antibodies elicited in infancy are unknown.
Serum IgGs are produced by antigen-specific B cells that have
undergone activation, proliferation, IgM to IgG switch, selection,
and differentiation within germinal centers (GCs). This process
generates a subset of post–germinal center B cells that are
committed to the plasma cell fate (ie, express Blimp-1 and secrete
antigen-specific Ig).17,18 Referred to as plasmablasts (PBs), they are
not yet in the G0/G1 phase and exhibit surface markers of both
mature B cells and plasma cells (PCs: B220low, CD19,
CD138).19-21 These cells undergo final differentiation into PCs
that secrete such high amounts of antibodies that serum antibody
levels may be maintained by a small population of antibody-
secreting cells (ASCs).20 As the half-life of IgG molecules in serum
is only 3 weeks, the maintenance of serum antibody levels requires
the persistence of ASCs.
There is strong evidence that the longevity of PCs is regulated
by their environment19 (ie, their access to survival niches). At the
exit of GCs, PBs express CXCR4 and respond to CXCL12 by
migration toward environmental niches22-25 primarily located within
the bone marrow (BM),26 where they receive additional signals
required for their differentiation into long-term surviving PCs.17
The role of these long-lived PCs, versus memory B cells, in the
maintenance of antibody titers was recently demonstrated in
Cr2-deficient mice.27 The characteristics of BM PC niches (ie, cell
types, size, accessibility, ontogeny, dynamics, etc) are still poorly
defined.28 Recent work demonstrated that BM IgG PCs are in
direct contact with BM stromal cells (BMSCs) expressing VCAM-1
and CXCL12.29 Factors contributing to the maintenance of BM PCs
include CXCL12, interleukin (IL)-6, tumor necrosis factor (TNF)-,
CD44 ligands, B cell–activating factor/B-lymphocyte stimulator (BAFF/
BLyS), and a proliferation-inducing ligand (APRIL).30-32 In contrast to
the factors contributing to the maintenance of PCs, little is known on the
cells and factors required to support the short but critical transition stage
during which apoptosis-prone PBs must survive and undergo terminal
differentiation into PCs.
Using neonatal murine immunization models that reflect to a
large extent the human immune maturation process observed in
neonates and infants,33-35 we observed that the establishment of the
BM pool of ASCs is delayed and deficient in early life.36 Even the
repeat administration of immunogens eliciting adultlike secondary
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responses in the spleen of infant mice was not followed by the
successful establishment of specific ASCs in the BM.37 This
reflects limitations that do not affect neonatal B cells but the BM
compartment. Indeed, adoptively transferred spleen PBs generated
in neonates or in adults efficiently reach the early-life BM
compartment.38 Most PBs transferred into adult recipients persist in
the BM, whereas most (70%) PBs reaching the early-life BM
compartment disappear within 30 hours, undergoing a significantly
higher rate of apoptosis.38 This limited persistence of PBs in the
early-life BM compartment results from impaired support provided
by early-life BMSCs. Here we defined cellular and molecular
factors that support the survival of IgG PBs and that differ in the
early and adult BM compartments.
Methods
Mice
BALB/cByJ and C57BL/6 J mice (8-16 weeks) were purchased from
Charles River (L’Arbresle, France), bred, and kept under specific pathogen-
free conditions. APRIL/ and BAFF/ mice were gifts from Genentech
(San Francisco, CA) and BiogenIdec (Cambridge, MA), respectively.
Manipulations were carried out according to Swiss and European guide-
lines, and all experiments were approved by the Geneva Veterinary Office.
Antigens, adjuvants, and immunizations
BALB/c mice were immunized twice intraperitoneally at a 3-week interval
with TT (1 limit of flocculation per mouse; gift of Berna Biotech, Bern,
Switzerland) absorbed to Al(OH)3 (gift of Chiron, Siena, Italy). C57Bl/6
mice were primed with TT/Al(OH)3 with added CpG1826 oligonucleotides
(50 g)39 and boosted with TT-Al(OH)3 5 weeks after priming.
Expression constructs and transfection
For fluorescence-activated cell sorting (FACS), supernatants of HEK-293T
cells transiently transfected with Flag-ACRP-mAPRIL A88, Flag-ACRP-
mAPRIL H98, Flag-BAFF, or Flag-4–1BBL were used. For survival
experiments, Flag-ACRP-mAPRIL H98, Flag-mBAFF, and control Flag-
EDA2 molecules were from Apotech/Axxora (Epalinges, Switzerland).
Flag-ACRP-mAPRIL A88 was produced as previously described.40
BMSC cultures and plasmablast survival assays
Unless otherwise indicated, BMSC cultures (BMSCCs) were prepared as
previously described38 from BALB/c mice. At confluence (day 7-8),
supernatants were collected and cells lysed with TRIZOL (Invitrogen,
Carlsbad, CA). Survival assays were performed as described.38 In other
experiments, PBs were incubated in presence of APRIL A88, truncated
APRIL H98, BAFF, or EDA-2 as a control for 48 hours. PBs were
recovered at time 0 or after 48 hours of culture for enzyme-linked
immunosorbent spot (ELISpot) assay and survival rates were calculated as
follows: percentage of surviving ASCs  surviving ASCs/total ASCs
 100, where total ASCs was 1007 ( 394; mean  SD) depending on
culture. PBs were recovered at time 0 or after 48 hours of culture for FACS
analyses or after 24 hours for RNA extraction.
FACS staining
For staining of PBs before and 48 hours after culture, recovered cells were
incubated with 20% of 2.4G2 (anti-Fc) supernatant and then stained with
anti-B220 (Pharmingen, San Diego, CA) and anti-CD138. Propidium
iodide exclusion was performed to analyze live cells. For binding experi-
ments, PBs were incubated with 20% of 2.4G2 supernatant and stained with
various Flag-molecules. After washing and staining with biotin anti–flag
M2 antibody, detection was performed with streptavidin-Alexa 488 (Molecu-
lar Probes, Eugene, OR). Cells were analyzed using the FACScan (BD
Biosciences, Mountain View, CA) and CellQuest software (BD Immunocy-
tometry Systems, San Jose, CA).
Detection of survival factors
Supernatants of BMSCCs were harvested at days 1 and 5 and after 48 hours
of BMSC/PB coculture. The presence of survival factors was assessed by
sandwich enzyme-linked immunosorbent assays (ELISAs) using relevant
antibody pairs (clones MP5-20F3 and MP5-32C11 [Pharmingen] for IL-6;
clones 5A8 and 1C9 [Apotech/Axxora] for BAFF). Detection limits were
250 pg/mL (IL-6) and 1 ng/mL (BAFF).
In vivo plasmablast transfer
C57BL/6 adult mice were primed and boosted as described in “Antigens,
adjuvants, and immunizations.” Four days after boosting, splenocytes were
treated with ACK lysis buffer and 108 cells transferred intravenously to
recipient mice. Eighteen and 48 hours later, spleen and BM were recovered
for evaluation of TT-specific IgG ASCs by ELISpot. To calculate the total
number of ASCs in the BM, the number of ASCs/million cells was
multiplied by the number of cells recovered from both femurs and tibias and
by a coefficient of 5.3.41 Sera from transferred APRIL/, BAFF/, and
C57Bl/6 mice were taken at different time points after transfer and
TT-specific antibody titers determined by ELISA as previously described.39
APRIL immunostaining
Day-5 stromal cells were replated in 8-chamber culture slides (BD
Biosciences, Bedford, MA), at 5  104 cells/chamber. One day after, cells
were fixed in 1:1 methanol-acetone mix, preincubated with anti–mouse
IgG-HRP and rabbit IgG to reduce background, and stained overnight with
control or anti-APRIL hybridoma supernatants (IIID3; Apotech/Axxora).
Revelation was performed using anti–mouse IgG-Alexa (Sigma-Aldrich, St
Louis, MO) and DAPI staining. Alternatively, cells were stained by
biotin-conjugated anti–Mac-1 (M5/70) antibody, revealed by Qdot605-
streptavidin (Invitrogen), and coverslip was fixed with polyvinyl alcohol
mounting medium with DABCO (Fluka, Munich, Germany). Sections were
visualized and photographed with a Zeiss LSM510 Meta confocal micro-
scope (objectives: Plan Neofluar 20/0.5 and 40/1.3 oil) at room
temperature, and images were acquired with Zeiss LSM image browser
software (Zeiss, Feldbach, Switzerland).
Real-time quantitative PCR
Total cellular RNA of fresh BM or BMSCC was isolated and cDNA
synthesized as previously described.38 Total cellular RNA from PBs was
isolated by RNeasy microkit and 2-step amplification performed fol-
lowing supplier’s instructions (Affymetrix, Santa Clara, CA) to obtain
cRNA. cDNA was synthesized as previously described.38 Sybr green
assays and amplicons were designed as previously described.38 The
efficiency of each design was tested with serial dilutions of cDNA and
found to be more than 90% for all primer pairs. Polymerase chain
reaction (PCR) reactions were performed on a SDS 7900 HT instrument
(Applied Biosystems, Foster City, CA) in 3 replicates, with EEF and
TBP as internal controls genes for data normalization.42 The following
primers (Invitrogen) were used: IL-6–forward 5-CTATGAAGTTC-
CTCTCTGCAAGAGACT-3 and IL-6–reverse 5-GGGAAGGCCGT-
GGTTGTC-3, BAFF-forward 5-CCGCGGCCACAGGAA-3 and
BAFF-reverse 5-TGAGAGGTCTACATCTTGTTCTGTTTC-3,
APRIL-forward 5-TTTCACAATGGGTCAGGTGGTA-3 and APRIL-
reverse 5-AGGCATACTTCTGATACATCGGAAT-3, Bcl-XL–forward
5-CTGGGACACTTTTGTGGATCTCT-3 and Bcl-XL–reverse 5-AAG-
CGCTCCTGGCCTTTC-3, Blimp-1–forward 5-GTGCAGAGGTGAGGGT-
GTGTAG-3 and Blimp-1–reverse 5-GCCATCAAATGCGACTGGAT-3,
EEF1A1-forward 5-TCCACTTGGTCGCTTTGCT and EEF1A1-reverse 5-
CTTCTTGTCCACAGCTTTGATGA-3, and TBP-forward 5-TTGACCTA-
AAGACCATTGCACTTC-3 and TBP-reverse 5-TTCTCATGATGACTG-
CAGCAAA-3. Normalization factors and relative RNA expression were
calculated according to geNorm (http://medgen.urgent.be/	jvdesomp/genorm/)
as previously described.42
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Statistical analysis
Statistical differences between 2 groups were analyzed by Mann-Whitney
U test, and differences between multiple groups were analyzed by one-way
ANOVA followed by the Tukey multiple comparison test. Differences with
probability values more than .05 were considered insignificant.
Results
APRIL, but not BAFF, is critical for PB survival in vivo
The demonstrated importance of APRIL and BAFF/BLyS for the
generation of PCs prompted us to assess their role in early and adult
life, using our previously validated adoptive transfer experiments.38
In this model, splenic PBs generated in adult mice immunized with
TT-Al(OH)3 are harvested at the peak (day 4) of the booster
response and transferred intravenously prior to their quantification
in the BM early (18 hours) or late (48 hours) after transfer. The
number of ASCs that reached the BM at 18 hours allows the
quantification of in vivo homing, whereas ASCs recovered at
48 hours reflect PB survival in the BM compartment.38 We
postulated that if the limited expression of APRIL or BAFF/BLyS
by BM cells was critical for PB survival into the BM, a similar
pattern of normal homing but limited survival should be observed
in infant WT mice and in adult APRIL/ or BAFF/ mice.
The pattern of PB survival in vivo was thus assessed into adult
BAFF/, APRIL/, or wild-type C57Bl/6 mice. Similar numbers
of TT-specific ASCs were observed in the BM of WT C57Bl/6 and
BAFF/ mice 18 hours and 48 hours after transfer (Figure 1A),
indicating that BAFF is not required for early PB survival in vivo.
Similar numbers of TT-specific ASCs were also observed in the
BM of WT C57Bl/6 and APRIL/ mice (18 hours) after transfer,
indicating similar BM homing. In contrast, TT-specific ASCs
recovered 48 hours after transfer from the BM of APRIL/ mice
were significantly (3-fold) fewer than in WT mice (Figure 1B). No
difference was observed in the spleen between C57Bl/6, BAFF/,
or APRIL/ mice at any time point (not shown). Serum TT-
specific IgG titers remained significantly lower in adult APRIL/
than in C57BL/6 or BAFF/ mice up to the last time point
assessed (Figure 1C), confirming the limited capacity of the BM
compartment of APRIL/ mice to support PB survival/differentia-
tion. The role of APRIL in PB survival/differentiation was con-
firmed by the immunization of APRIL/ and WT mice, followed
by the quantification of ASCs early (day 7) after boosting. The
lower recovery of TT-specific ASCs in the BM of immunized adult
APRIL/ compared with WT mice (Figure 1D) confirmed that
APRIL, but not BAFF, is critical for PBs to establish themselves as
IgG-producing BM PCs.
Binding to proteoglycans confers a preferential PB-supporting
activity to APRIL
BAFF and APRIL may bind to both BCMA and TACI, in addition
to the binding of BAFF to BAFF-R and of APRIL to proteogly-
cans.43 To compare the relative capacity of APRIL and BAFF to
bind to murine PBs, PBs were incubated with graded concentra-
tions of Flag-APRIL or Flag-BAFF molecules and stained with
antiflag monoAb to estimate relative binding capacities. Flag-
BAFF and Flag-APRIL similarly bound to adult PBs (MFI
7.5  0.7 and 7.9 2.2, respectively; Figure 2A). As expected, the
preincubation of Flag-APRIL with heparin strongly decreased PB
binding, suggesting an important role of its interaction with
proteoglycans, confirmed by the limited binding of a truncated
Figure 1. APRIL is critical for the in vivo survival of BM plasmablasts. (A) Adult C57BL/6 mice were primed by intraperitoneal injection of TT/AlOH  CpG1826 and boosted
5 weeks later with TT/AlOH. Four days after boosting, splenocytes were harvested and transferred (100  106 per recipient mouse) into adult C57BL/6 BAFF/ or WT
recipients. Eighteen and 48 hours later, mice were killed and TT-specific IgG ASCs quantified by ELISpot in the BM compartment. Results are expressed as ASCs per organ
(mean  SD) obtained in one experiment including 4 mice per group and representing 2 independent experiments. (B) Adult C57BL/6 mice were primed by intraperitoneal
injection of TT/AlOH  CpG1826 and boosted 5 weeks later with TT/AlOH. Four days after boosting, splenocytes were harvested and transferred (100  106 per recipient
mouse) into adult C57BL/6 APRIL/ or WT recipients. Eighteen and 48 hours later, mice were killed and TT-specific IgG ASCs quantified by ELISpot in the BM compartment.
Results are expressed as ASCs per organ (mean SD) obtained in one experiment including 4 mice per group and representing 3 independent experiments. *P 
 .05 versus
adult WT mice. (C) In an independent experiment, sera from adoptive transfer recipients C57BL/6 APRIL/, BAFF/, or WT adult mice were harvested at different time points
after transfer and TT-specific antibody titer was determined by ELISA. *P 
 .05 WT versus APRIL/; **P 
 .05 BAFF/ versus APRIL/. (D) APRIL/ and C57BL/6 control
mice were immunized as described in “Antigens, adjuvants, and immunizations” and TT-specific IgG ASCs were quantified by ELISpot in the BM 7 days after boost. Results are
expressed as ASCs per million (mean  SD) obtained in 2 experiments including 6 to 10 mice per group *P 
 .05 versus adult WT mice.
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APRIL molecule (H98) in which the heparan sulfate proteoglycan
(HSPG) binding region is deleted44 (Figure 2A).
To compare the relative capacity of APRIL and BAFF to
support PB survival, TT-specific PBs were cultured in presence of
recombinant ligands, prior to the quantification of TT-specific
ASCs. In vitro, both BAFF and APRIL supported the recovery of
ASCs (Figure 2B). However, the PB-supporting capacity of APRIL
was dose dependent and reached significantly higher levels than
that of BAFF. Interestingly, APRIL A88 was more efficient than
truncated APRIL H98 (Figure 2B). This reflects the differential
binding of APRIL A88 and H98 to HSPG rather than different
concentrations of bioactive APRIL in these preparations, as the
proliferation of B cells was similarly supported by APRIL H98 and
APRIL A88 (Figure S1, available on the Blood website; see the
Supplemental Materials link at the top of the online article).
BAFF and APRIL were both reported to block B-cell antigen
receptor–induced apoptosis upstream of mitochondrial damage,
suggesting a role for Bcl-2 family proteins. That APRIL may
support PB survival in vitro better than BAFF was confirmed by an
enhanced expression of Bcl-XL in PBs incubated with APRIL but
not BAFF (Figure 2C). This was not associated with an increase of
Blimp-1, indicating no direct influence of APRIL on PB to PC
differentiation (Figure 2C). Altogether, these observations confirm
that both BAFF and APRIL may support PB survival in vitro but
show that the critical advantage of APRIL for PB survival results
from its binding to HSPG on PB.
Early-life BMSCs fail to support plasmablast survival
We next used primary BMSCCs to better define the cellular
components of the BM niches that support PB survival. Splenic
PBs harvested at the peak of the response (ie, day 4 after TT
boosting) were cultured ex vivo for 48 hours on a monolayer of
enriched BMSCs, generated as previously described,38 prior to the
quantification of TT-specific ASCs. The recovery of TT-specific
ASCs was markedly ( 6-fold) higher when PBs were incubated
on enriched BMSCs than with freshly isolated total BM cells or in
medium alone (Figure 3A). This enrichment of the PB-supporting
capacity of adult BMSCs was associated with a high proportion of
cells defined as nonimmediately adherent, Mac-1, F4/80, and
Gr-1 cells (Figure S2A,B). CD3 T cells and B220high B cells
were present at percentages less than 10% each. These prominent
Mac-1F4/80 BMSCs belong to the lineage of “tissue-resident
macrophages” since they are CD11cint but CCR2 (Figure S2C).
Moreover, all Mac-1F4/80 BMSCs expressed MHCII but few
expressed VCAM-1 and some displayed an intermediate expres-
sion of Thy-1. Thus, BMSCCs with enriched PB-supporting
capacity were a heterogeneous population in which resident
macrophages were the main cell population.
To characterize the acquisition of the PB-supporting capacity of
BMSCs during ontogeny, PBs were cultured ex vivo on enriched
BMSCs generated from 2-week-old, 4-week-old, or adult mice. As
previously reported,38 few TT-specific ASCs were recovered when
adult PBs were seeded on 2-week-old BMSCs (Figure 3B). In
Figure 2. Similar binding of APRIL and BAFF to
plasmablasts but preferential survival support medi-
ated by APRIL. Recombinant trimeric murine molecules
were tested for their capacity to (A) bind to PBs and
(B) support the recovery of TT-specific ASCs. (A) Purified
PBs (2  105, isolated by CD138 staining) were incu-
bated with 500 nM of a murine Flag-recombinant mole-
cule (BAFF, APRIL A88, truncated APRIL H98, or control
molecule [4–1BB-L]), with or without preincubation with
heparin as indicated. The binding to PBs was revealed by
antiflag staining. (B) Purified PBs were seeded into
96-well plates (5  103 cells/well) in presence of different
concentrations of recombinant murine molecules (com-
plete APRIL A88, truncated APRIL H98, BAFF, or EDA-2
control molecule). TT-specific IgG ASCs were enumer-
ated by ELISpot initially and after 48 hours of culture and
survival expressed as mean ( SD) of 3 independent
cultures. *P 
 .05 versus PB cultured with the same
concentration of control molecule. **P 
 .05 versus PB
cultured with the same concentration of BAFF. ***P 
 .05
versus PB cultured with same concentration of the
truncated APRIL H98. (C) The expression of Bcl-XL and
Blimp-1 by PBs was evaluated by quantitative real-time
reverse-transcription (RT)–PCR at onset (ex vivo) and
after 24 hours of culture with 300 ng/mL of molecule.
Results are expressed as the fold change of transcript
expression for each condition of culture compared with
t0 obtained from 1 representative experiment (pool of
10 mice) of 2.
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contrast, the proportion of TT-specific ASCs was similar when PBs
were cultured on 4-week-old or adult BMSCs (Figure 3C). The
limited PB-supporting capacity of BMSCs is thus early-life spe-
cific. The proportion of Mac-1F4/80 cells was similar (70% to
85%) in 2-week-old and adult BMSCs. (Figure S2B). Thus, the
limited PB-supporting capacity of early-life BMSCs does not
reflect a delayed ontogeny of Mac-1F4/80 cells, but does reflect
differences in their functional capacity.
Adult BMSCs might enhance the recovery of TT-specific ASCs
by supporting PB proliferation, survival, and/or PC differentiation.
Their influence on proliferation was first assessed by adding
hydroxyurea, a proliferation-blocking agent,31 during PB culture on
adult BMSCs. This did not affect the recovery of TT-specific ASCs
(Figure S3A), although it completely blocked the LPS-induced
proliferation of splenic B cells (Figure S3B). Accordingly, the
analysis of CFSE-labeled PBs did not indicate that cell division
occurs during coculture on adult BMSCs. CFSE staining profiles
were the same 24 hours or 48 hours after coculture initiation and
unaffected by the presence of hydroxyurea (Figure S3C).
The role of BMSCs on PB survival/differentiation was assessed
by defining their influence on PB phenotype. Culture of CD138
cells with adult BMSCs or IL-6 generated more live cells than
culture with 2-week-old BMSCs or medium only (Figure 4A),
consistent with results of ASC frequencies obtained by ELISpot. A
contamination by BMSCs was excluded since PBs recovered after
BMSC coculture contained less than 2% of Mac-1 cells (not
shown). The percentage of PBs (CD138intB220int) markedly de-
creased between time 0 (t0: 42% to 63%) and 48 (5% to 17%) hours
after culture, while the proportion of mature B cells
(CD138B220high), prePBs (CD138intB220high), and PBs recovered
after 48 hours remained unchanged in the different cultures,
confirming that the cultures essentially influence terminal B-cell
differentiation (Figure 4B,C). PC differentiation was enhanced by
the addition of IL-6, which increased the number of PCs and
prePCs (Figure 4B,C) and the expression of Blimp-117,45,46 by
CD138 cells (Figure 4D). Culture on adult BMSCs yielded a
higher proportion of live PCs than when PBs were cultured in
medium alone or on 2-week-old BMSCs (Figure 4B,C). Thus, adult
BMSCs were more potent than 2-week-old BMSCs for supporting
the survival/differentiation of PBs/PCs. The distinction between
such closely related events is not trivial. However, a marked
enhancement of Bcl-XL expression by CD138 cells, contrasting
with the lack of increase of Blimp-1, was observed upon PB culture
on enriched adult BMSCs (Figure 4D). In accordance with
previous observations,47 this indicates that enriched adult BMSCs
essentially support survival. Remarkably, this increase in Bcl-XL
expression was not observed when PBs were cultured on 2-week-
old BMSCs (Figure 4D), demonstrating their limited capacity to
provide sufficient survival signals. Thus, BMSCs directly support
PB/PC survival, but this functional capacity is acquired only
between 2 and 4 weeks after birth.
Early-life BMSCs fail to express adult levels of APRIL
We next asked whether the support of PB survival conferred by
BMSCs was mediated by BAFF/BLyS, APRIL, or IL-6, known to
contribute to PC survival.30-32 IL-6 mRNA was present at very low
levels in BM cells ex vivo (total BM cells, Ct  31.8  0.4), on
day 6 of culture or after 48 hours of coculture with PBs
(Ct  33.06  1.4, Figure 5A). Accordingly, IL-6 concentration
remained below detection level in BMSCC supernatants (not
shown). IL-6 is therefore not required for PB survival in our
experimental system. BAFF mRNA was strongly expressed ex
vivo in total adult BM cells (Ct  25.5  0.6, Figure 5B). How-
ever, BMSCCs expressed only low levels of BAFF
(Ct  28.4  0.6, Figure 5B), which remained below detection
level when assessed by ELISA (not shown). In contrast, the
expression of APRIL mRNA was much higher in adult BMSCCs
(Ct  23.8  0.5) than ex vivo in total BM cells (Ct  25.5  0.6,
Figure 5C). The availability of a novel antimurine APRIL hybrid-
oma supernatant whose reactivity is negative on control APRIL/
cells (Figure S4A) allowed to confirm APRIL protein expression by
adult enriched BMSCs (Figure 5D). Confocal microscopic analy-
ses confirmed Mac1 cells as the main APRIL-producing BMSCs
(Figure 5E). Western blot analyses (not shown) and FACS staining
(Figure S4B) were not sufficiently sensitive to detect baseline
APRIL expression in BMSCs.
The comparative expression of IL-6, BAFF, and APRIL was
assessed in 2-week-old, 4-week-old, and adult BM cells. IL-6
expression remained weak in all samples (Figure 5A). In the total
BM cell population, the expression of BAFF increased during
ontogeny (Figure 5B). However, BAFF was as weakly expressed
by day-6 BMSCs generated in early life as in those from adult
controls. In contrast, the expression of APRIL mRNA was signifi-
cantly higher in 4-week-old or adult BMSCs than in 2-week-old
BMSCs (Figure 5C). This was associated with a stronger protein
expression of APRIL in adult BMSCs than in 2-week-old BMSCs
(Figure 5D). APRIL expression was assessed ex vivo in Mac-
1Gr1low cells sorted from the BM of adult and 2-week-old mice
Figure 3. Ontogeny of the BMSC plasmablast-supporting capacity. (A) The
capacity of BM cells to support the recovery of TT-specific ASCs was evaluated in
coculture experiments. Fresh total BM cells from 5 individual mice were seeded
immediately after harvesting into 96-well plates at a density of 5  104 cells/well.
Enriched BMSCs generated from a pool of 10 10-week-old mice were generated by
5 days of culture as described in “BMSC cultures and plasmoblast survival assay”
and reseeded at the same density. TT-specific splenic PBs (5  103) purified by
anti-CD138 AutoMACS (Miltenyi Biotech, Bergisch Gladbach, Germany) sorting
were added 24 hours later. Control wells contained PBs incubated in medium alone or
with 10 ng/mL recombinant murine IL-6. TT-specific IgG ASCs were enumerated by
ELISpot at the onset and after 48 hours of culture. The proportion of surviving PBs
was calculated (recovered TT-specific ASCs/initial TT-specific ASCs  100) and
expressed as the mean ( SD) of 6 independent cultures. *P 
 .05 versus coculture
of PB with adult total BM cells. (B) Similar experiments were performed with enriched
BMSCs generated from a pool of fifteen 2- or 10-week-old (control) mice. Results are
expressed as the mean ( SD) of 6 independent cultures per age group. One
representative experiment of 3 is shown. *P 
 .05 versus adult enriched BMSCs.
(C) Similar experiments were performed with enriched BMSCs generated from a pool
of fifteen 4- or 10-week-old (control) mice. Results are expressed as the mean ( SD)
of 6 independent cultures per age group. One representative experiment of 3 is
shown. Error bars represent SD.
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(mean relative mRNA expression: 1.60 vs 0.42, respectively),
confirming the limited expression of APRIL by early-life BM-
resident Mac-1 cells. Despite the insufficient sensitivity of current
protein detection assays, the direct correlation between PB-
supporting capacity and the expression of APRIL mRNA strongly
suggests that the limited expression of APRIL by early-life BMSCs
is insufficient to provide optimal PB survival signals.
Discussion
The present study demonstrates that the transition of antigen-
specific splenic IgG plasmablasts into ASCs that survive in the BM
compartment is a critical stage that requires the expression of
APRIL by BMSCs and its interaction with HSPG at the PB surface.
It establishes that this process is inefficient in early life, limiting the
establishment of the BM PC pool.
To study the terminal differentiation of in vivo–generated
PBs, we took advantage of the synchronization of secondary
responses that may be achieved by booster immunization. Pilot
experiments indicated that on day 4 after boost with a strong
immunogen (TT) adsorbed to alum, more than 90% of splenic
IgG-secreting cells are TT-specific PBs capable of migrating
toward CXCL1238 or the BM compartment.38 Using this physio-
logical source of Ag-specific PBs, we observed that PBs rapidly
die ex vivo unless they receive specific support from BMSCs,
and investigated which cell types mediate this support. Recent
studies established that BM IgG PCs are in contact with
VCAM- and CXCL12-expressing BMSCs.29 Phenotypic anal-
yses indicated that these BMSCs belong to fibroblast-like
reticular cells29 that may be enriched by Whitlock-type long-
term BM cultures and support the maintenance of murine PC
longevity30 or the final differentiation of human blood–derived
or BM-derived early PCs.48-50 Such BMSCs represent a hetero-
geneous population. In our hands, freshly isolated total murine
BM cells provided very little PB support (Figure 3A). In
contrast, culture conditions optimized to enhance the recovery
of nonimmediately adherent Mac1, F4/80, Gr-1 cells (Fig-
ure S2) reliably lead to a marked increase of the survival of
TT-specific PBs. These cells belong to the hematopoietic
lineage, and more specifically to BM-resident macrophages. We
cannot exclude that another minor population could also have
PB-supporting capacity since the low yield of BMSCs did not
allow to recover enough cells with more than 90% purity from
Figure 4. Adult enriched BMSCs support plasmablast survival. (A-C) Purified PBs (5  103) were added on adult enriched BMSCs or 2-week enriched BMSCs, or
incubated with medium or IL-6. (A) The viability of recovered cells was analyzed by FACS 48 hours after culture using propidium iodide exclusion. Results are expressed as the
mean ( SD) of 4 independent cultures per condition. *P 
 .05 versus 2-week enriched BMSCs. **P 
 .05 versus medium. (B) FACS panels for expression of B220 and
CD138 for one culture per each condition representing 4 independent cultures. Percentages of each subset gated on live cells are shown on the plots. (C) Percentage of each
subset gated on live cells determined by FACS staining as described in panel A. Results are expressed as the mean ( SD) of 4 independent cultures per each condition.
*P 
 .05 versus 2-week enriched BMSCs. **P 
 .05 versus medium. (D) The expression of Bcl-XL and Blimp-1 by PBs was evaluated by quantitative real-time RT-PCR at
onset (ex vivo) and after 24 hours of culture. Results are expressed as the fold change of transcript expression for each condition of culture compared with t0 (mean  SD)
obtained from 3 independent cultures each representing a pool of 10 mice. *P 
 .05 versus 2-week enriched BMSCs. **P 
 .05 versus medium.
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other populations. However, the parallel increase of the number
of BM-resident macrophages and of the PB-supporting capacity
suggests that they are an important component of the PB-
supporting hematopoietic BM niches.
BMSCs might support antigen-specific ASCs by enhancing ex
vivo PB proliferation However, the use of a proliferation-blocking
agent and the tracking of PB divisions (Figure S3) indicated that
TT-specific PBs do not proliferate when cultured on BMSCs. Adult
BMSCs did not significantly enhance the PB expression of
Blimp-1, which regulates Ig secretion and the final differentiation
of PBs into PCs.45 In contrast, adult BMSCs induced a significant
increase in antiapoptotic gene (Bcl-XL) expression (Figure 4),
which was associated with a high level of surviving CD138 cells,
in particularly PCs. Altogether, this demonstrates that BMSCs
essentially support PB survival, enabling the surviving cells to
undergo their differentiation into PCs under the influence of
additional signals such as IL-6 (Figure 4). This is in accordance
both with the proapoptotic state of PBs51 and the role of Bcl-xL in
mediating PC survival.47,52
Factors identified as supporting the survival of PCs include
CXCL12, IL-6, BAFF/BLyS, and APRIL. We previously re-
ported the similar CXCL12-mediated homing of PBs to the early
life and adult BM,38 and thus focused here on IL-6, BAFF/BLyS,
and APRIL. Whitlock-derived BM stromal cell lines support PC
survival and differentiation in an IL-6–dependent manner.31 The
exogenous addition of IL-6 supports the recovery of TT-specific
Figure 5. Delayed ontogeny of APRIL expression by
BM cells. The expression of mRNA IL-6 (A), BAFF (B),
and APRIL (C) was evaluated by quantitative real-time
RT-PCR on fresh BM cells and on BMSCs from 2-week-
old, 4-week-old, and adult mice. Results include data
generated with a pool of 6 to 7 individual mice (total BM
cells) or 5 independent cultures of a pool of 10 mice
(enriched BMSCs). *P 
 .05. (D) BMSCs (5  104) from
adult and 2-week-old mice were stained in chamber
slides with IIID3 antibody as described in “APRIL immuno-
staining.” (E) BMSCs (5  104) from adult mice were
stained in chamber slides with IIID3 antibody and anti–
Mac-1 antibody as described in “APRIL immunostaining.”
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ASCs, in a dose-dependent manner (Figure 3 and data not
shown). However, IL-6 was weakly expressed in total BM cells
and did not increase in day-6 BMSCCs despite a marked
enrichment in PB-supporting function. Coculture with PBs31,53
did not increase IL-6 expression by BMSCs. Accordingly, IL-6
is not required for the establishment of the BM PC pool in vivo,
as demonstrated in IL-6/ mice.31 Altogether, this suggests that
IL-6 essentially supports PB differentiation into PCs, as evi-
denced by its influence on Blimp-1 expression (Figure 4),
whereas other molecules are critical for PB survival.
The implication of BAFF/BLyS and APRIL in PC survival
was recently established.32,44,54,55 These 2 TNF family ligands
that share many characteristics may be expressed by a large
series of cells (monocytes, macrophages, dendritic cells, neutro-
phils, T cells, osteoclasts, BMSCs, and nurselike cells).43 The
depletion of both BAFF and APRIL, by the administration of the
TACI-Ig decoy receptor or through the genetic invalidation of
the BAFF/APRIL-binding BCMA receptor, depletes the BM PC
pool.32 Although these ligands are critical players in the
maintenance of PCs, their respective contribution remains to be
defined.43 BAFF and APRIL enhance the ex vivo survival of PBs
generated in vitro from human memory B cells.56 Their influ-
ence on recently generated in vivo PCs was recently addressed
by treating mice on day 6 after immunization with either
BCMA:Fc or BAFF-R:Fc.44 The frequency of BM antigen-
specific PCs was dramatically decreased only in mice treated
with BCMA:Fc, strongly suggesting the importance of APRIL
(either alone or with BAFF) for the migration and/or the
survival of BM-resident PCs.44
Our results demonstrate that although both BAFF and APRIL
bind to PBs and support their survival ex vivo, APRIL exerts a
critical role (Figure 2). The expression of APRIL, but not that of
BAFF, parallels the increase in the PB-supporting capacity of
adult BMSCs (Figure 5). Furthermore, the transfer of TT-
specific PBs in BAFF/ mice demonstrates that BAFF does not
play a critical role in supporting PB survival in vivo (Figure
1A). In contrast, the same transfer in APRIL/ mice formally
demonstrates that despite normal homing TT-specific PBs fail to
establish efficiently as persisting ASCs in the BM compartment
of APRIL/ mice (Figure 1B), which results into a shorter
persistence of serum TT-specific IgG titers (Figure 1C). In a
more physiological immunization model, the significantly lower
number of TT-specific ASCs in the BM compartment of
APRIL/ adult mice early after boosting confirms that the
absence of APRIL is sufficient to markedly limit the establish-
ment of the BM ASC pool (Figure 1D).
These results are the first to directly decipher the distinct
roles of APRIL and BAFF in PB survival in vivo. The frequency
of antigen-specific BM ASCs was dramatically reduced when
BAFF and APRIL (but not of BAFF alone) were blocked by
BCMA-Ig administration one week after immunization.44 This
in accordance with a main role of APRIL on PB rather than PC
survival. Interestingly, the number of total IgG-producing BM
ASCs is similar in adult APRIL/ (60  103/mouse) and WT
(35  103/mouse) mice, explaining why the PB-supporting
function of APRIL was not identified earlier.57,58 The same is
true for IL-6/ mice, which have normal numbers of PBs/PCs
in their BM despite evidence for the role of IL-6 in PC
differentiation.31 This could reflect the implication of yet-
unidentified PB/PC survival/differentiation factors. Alterna-
tively, some PBs may escape from apoptosis and survive long
enough to terminally differentiate into PCs that slowly accumu-
late in the BM, supported by PC survival factors. Thus,
APRIL-blocking strategies currently considered for use in autoim-
mune conditions43 may have a greater impact on recently generated PBs
than on successfully established long-lived PCs.
How may the relative contribution of APRIL and BAFF to
PB survival be so distinct? Despite many common characteris-
tics, APRIL and BAFF show considerable differences with
respect to receptor binding. BAFF binds to BAFF-R, BCMA,
and TACI, whereas APRIL binds to BCMA, TACI, and proteo-
glycans.43,59 As B-cell differentiation proceeds toward PBs and
PCs, the expression of TACI and of BAFF-R decreases, whereas
that of BCMA increases.43 Biacore studies using recombinant
ligands and receptor-Fc fusion proteins have indicated that
APRIL binds with much higher affinity to monomeric BCMA
than BAFF does, although this difference in no longer seen with
dimeric BCMA-Ig,60 suggesting a potential predominance of the
APRIL-BCMA axis. In addition, HSPGs were described as
APRIL-specific binding partners,44,61 and syndecan-1 PCs
display a highly specific binding of APRIL sensitive to inhibi-
tion by heparin.44 We observed that TT-specific PBs bind to
APRIL in a heparin-blocking manner, with a residual staining
attributed to BCMA and/or TACI binding (Figure 2). Binding of
APRIL to PB HSPGs likely contributes to promote PB survival,
because a truncated H98 APRIL molecule deprived of the basic
sequence (QKQKKQ) responsible for HSPG binding is less
efficient.44 Remarkably, proteoglycans (such as Syndecan-1) are
expressed at increasingly high levels as Blimp-1–regulated
B-cell differentiation progresses toward differentiated PCs.
HSPG may convert soluble proteins into a 2-dimensional array
that enhances further molecular encounters,62 protect ligands
from degradation, or support further oligomerization.63 The
binding of APRIL to HSPG may thus be a prerequisite for
signaling through BCMA (or possibly TACI) molecules ex-
pressed at the PB/PC stage.56 Thus, the yet elusive biologic
purpose for APRIL binding to HSPG43 may be to support PB
survival at a transient—but critical—stage of their differentia-
tion into PCs.
The physiological importance of APRIL expression by
BMSCs for PB survival in the BM compartment is further
evidenced by the identification of a physiological situation
during which this process is impaired. We previously reported
that the establishment of the BM ASC pool is delayed and
limited in infant BALB/c mice37 and that this reflects the limited
survival of PBs reaching the early-life BM.38 Here, we show that
several weeks2-4 of postnatal maturation are required for the BM
to provide an adultlike PB support. Given the rapid kinetics of
the postnatal maturation of murine secondary lymphoid organs,
this maturation process is remarkably slow. The only molecular
difference currently identified between PB-supporting adult
BMSCs and non–PB-supporting BMSCs generated from infant
mice is that of a limited expression of APRIL. Formal evidence
that APRIL is the critical factor that limits the establishment of
the BM ASC pool in early life is difficult to generate. However,
the demonstration that adult PBs survive similarly poorly when
transferred into the BM compartment of WT infant mice and of
APRIL/ mice, and that APRIL expression is the only currently
identified factor better expressed by adult PB-supporting than
infant non–PB-supporting BMSCs are strong arguments in
support of a critical role for APRIL. We do not yet know whether
the extensive similarities previously demonstrated in early-life
murine and human IgG responses will extend to include
limitations of the same BM-derived PB survival factors. Should
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this prove to be the case, the rapid waning of antigen-specific
antibodies elicited in early human life and the associated
resurgence of vulnerability to infections could remain a chal-
lenge difficult to meet without booster immunizations.
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